GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opiant Pharmaceuticals Inc (STU:8OP) » Definitions » Quick Ratio

Opiant Pharmaceuticals (STU:8OP) Quick Ratio : 5.48 (As of Sep. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Opiant Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Opiant Pharmaceuticals's quick ratio for the quarter that ended in Sep. 2022 was 5.48.

Opiant Pharmaceuticals has a quick ratio of 5.48. It generally indicates good short-term financial strength.

The historical rank and industry rank for Opiant Pharmaceuticals's Quick Ratio or its related term are showing as below:

STU:8OP' s Quick Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.82   Max: 10.46
Current: 5.48

During the past 13 years, Opiant Pharmaceuticals's highest Quick Ratio was 10.46. The lowest was 0.01. And the median was 0.82.

STU:8OP's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.515 vs STU:8OP: 5.48

Opiant Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Opiant Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals Quick Ratio Chart

Opiant Pharmaceuticals Annual Data
Trend Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Dec18 Dec19 Dec20 Dec21
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.59 2.99 7.00 9.21 10.10

Opiant Pharmaceuticals Quarterly Data
Oct17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.23 10.10 8.71 9.56 5.48

Competitive Comparison of Opiant Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Opiant Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opiant Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's Quick Ratio falls into.



Opiant Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Opiant Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Quick Ratio (A: Dec. 2021 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(61.206-0)/6.059
=10.10

Opiant Pharmaceuticals's Quick Ratio for the quarter that ended in Sep. 2022 is calculated as

Quick Ratio (Q: Sep. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(38.933-0)/7.11
=5.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Opiant Pharmaceuticals  (STU:8OP) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Opiant Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Opiant Pharmaceuticals (STU:8OP) Business Description

Traded in Other Exchanges
N/A
Address
233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.

Opiant Pharmaceuticals (STU:8OP) Headlines

No Headlines